Esperion (ESPR)

Company Description

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, once-daily, oral therapies to lower levels of low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is “patient-friendly, physician-friendly, and payer-friendly”.

COMPANY ADDRESS
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108

COMPANY PHONE
734-887-3903

COMPANY WEBSITE



Get BioInvest's perspective on Esperion's CEO


Latest Company News

Street Session Update on Esperion Therapeutics, Inc. (NASDAQ:ESPR) Rockville Register - Apr 26, 2017 Let's take a quick look at where covering equity analysts see Esperion Therapeutics, Inc. (NASDAQ:ESPR) going in the future. Zix (ZIXI) Reaches $5.61 After 8.00% Up Move; Shorts at Esperion Therapeutics ... - HuronReport Are Institutions Putting Their Stamp of Approval On Esperion Therapeutics, Inc ... - Midway Monitor [...]
Wed, Apr 26, 2017 10:07:00 PM, Continue reading at the source
Analyst's Predictions on Esperion Therapeutics, Inc. (ESPR), Fiesta Restaurant ... StockNewsJournal - Apr 25, 2017 ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business. [...]
Tue, Apr 25, 2017 6:56:00 PM, Continue reading at the source
Esperion Therapeutics Inc (ESPR) Given Average Rating of "Buy" by Brokerages The Cerbat Gem - Apr 25, 2017 Esperion Therapeutics logo Esperion Therapeutics Inc (NASDAQ:ESPR) has earned an average recommendation of “Buy” from the thirteen brokerages that are covering the firm. Does Esperion Therapeutics, Inc. (ESPR)'s current closing price competes the ... - TopChronicle Short Interest in Esperion Therapeutics Inc (ESPR) Increases By 19.6% - Markets Daily [...]
Tue, Apr 25, 2017 5:48:00 PM, Continue reading at the source
Option Market Alert: Esperion Therapeutics Inc Implied Price Swing Hits An ... CML News - Apr 23, 2017 Risk Alert: Before we dive into any analysis we simply note that Esperion Therapeutics Inc (NASDAQ:ESPR) risk is elevated. We'll detail it below -- but that's the lede -- the option market is starting to flash those neon lights that signal "risk is ... Citigroup Inc Raises Esperion Therapeutics Inc (ESPR) Price Target to $77.00 - Markets Daily How These Biotech Stocks are Faring? -- ACADIA Pharma, Alexion Pharma, TG ... - PR Newswire (press release) [...]
Sun, Apr 23, 2017 12:22:00 AM, Continue reading at the source
Esperion Therapeutics Inc Risk Points versus Health Care CML News - Apr 13, 2017 This is a scatter plot analysis of the critical risk points from the option market for Esperion Therapeutics Inc (NASDAQ:ESPR) compared to its own past and the Health Care ETF. [...]
Thu, Apr 13, 2017 1:50:00 PM, Continue reading at the source
Could Pfizer Buy Esperion Therapeutics? Motley Fool - Mar 31, 2017 By no coincidence (yet, confusingly!) that company was also named Esperion Therapeutics (let's call that one Esperion 1.0). Esperion Therapeutics Inc (ESPR) Given Average Rating of “Buy” by Brokerages - Sports Perspectives The Way Wall Street Experts See Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Post Analyst [...]
Fri, Mar 31, 2017 12:11:00 PM, Continue reading at the source
Esperion Therapeutics stock surges 52% after it says the FDA gave its drug ... MarketWatch - Mar 20, 2017 Esperion Therapeutics Inc. ESPR, -0.19% shares surged 52.0% in morning trade Monday after the company said the Food and Drug Administration gave it positive feedback on a cholesterol-lowering drug, saying that the late-stage program is enough to ... Esperion Therapeutics Rockets 70% Higher After Big Selloff - Benzinga [...]
Mon, Mar 20, 2017 3:01:00 PM, Continue reading at the source
Here's Why Amgen, The Medicines Company, and Esperion Therapeutics Are All ... Motley Fool - Mar 17, 2017 Among them were Esperion Therapeutics (NASDAQ:ESPR) and The Medicines Company (NASDAQ:MDCO), which dropped by 21% and 14%, respectively, by mid-day. Esperion Falls Victim To Amgen's Poor Repatha Results - Benzinga Amgen Blew It…For Medicines Co., Esperion Too - Barron's (blog) [...]
Fri, Mar 17, 2017 5:15:00 PM, Continue reading at the source
Here's Why Esperion Therapeutics Inc Stock Popped Today Motley Fool - Mar 1, 2017 Shares of Esperion Therapeutics Inc (NASDAQ:ESPR), a clinical-stage biotech focused on cholesterol-lowering treatments, popped late in Wednesday's session. Analyst Upgrades – Esperion Therapeutics (NASDAQ:ESPR) Stock Gets Upgraded By ... - Market Exclusive Esperion Therapeutics Inc (ESPR) is Upgraded by Citigroup to ” Buy” - Highland Mirror [...]
Wed, Mar 01, 2017 9:22:00 PM, Continue reading at the source
Why Esperion Therapeutics, Inc. Is Soaring Today Motley Fool - Feb 3, 2017 Shares of Esperion Therapeutics (NASDAQ:ESPR), a clinical-stage biopharma focused on developing drugs that treat cardiovascular disease, jumped 24% as of 3:15 p.m. Esperion Therapeutics (ESPR) 'Significantly Undervalued' Despite Move ... - StreetInsider.com [...]
Fri, Feb 03, 2017 8:38:00 PM, Continue reading at the source